Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 87-102 , February 2009

The role of the pancreatic endocannabinoid system in glucose metabolism

  • Francisco J. Bermúdez-Silva, PhD (Senior Research Fellow)

      Affiliations

    • Laboratorio de Medicina Regenerativa, Fundación IMABIS, Hospital Carlos Haya, Avda. Carlos Haya, Pabellón de Gobierno, sótano, 29010, Málaga, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 952614012.
    • ,
  • Juan Suárez Pérez, PhD (Postdoctoral fellow)

      Affiliations

    • Laboratorio de Medicina Regenerativa, Fundación IMABIS, Hospital Carlos Haya, Avda. Carlos Haya, Pabellón de Gobierno, sótano, 29010, Málaga, Spain
    • ,
  • Angel Nadal, PhD (Group Leader)

      Affiliations

    • Instituto de Bioingeniería and CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Universidad Miguel Hernández de Elche, Elche 03202, Alicante, Spain
    • ,
  • Fernando Rodríguez de Fonseca, MD (Group Leader)

      Affiliations

    • Laboratorio de Medicina Regenerativa, Fundación IMABIS, Hospital Carlos Haya, Avda. Carlos Haya, Pabellón de Gobierno, sótano, 29010, Málaga, Spain

References 

  1. Baker J, Olsen L, Sørensen T. Childhood body-mass index and the risk of coronary heart disease in adulthood. The New England Journal of Medicine. 2007;357:2329–2337
  2. Bibbins-Domingo K, Coxson P, Pletcher M, et al. Adolescent overweight and future adult coronary heart disease. The New England Journal of Medicine. 2007;357:2371–2379
  3. Roberts E. Pediatric nonalcoholic fatty liver disease (NAFLD): a ‘growing’ problem?. Journal of Hepatology. 2007;46:1133–1142
  4. Cervino C, Pasquali R, Pagotto U. Cannabinoid receptor antagonists and the metabolic syndrome: novel promising therapeutical approaches. Mini Reviews in Medicinal Chemistry. 2007;7:21–30
  5. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism: TEM. 2007;18:27–37
  6. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience. 2005;8:585–589
  7. Van Gaal L, Rissanen A, Scheen A, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  8. Pi-Sunyer F, Aronne L, Heshmati H, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA: The Journal of the American Medical Association. 2006;295:761–775
  9. Després J, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicine. 2005;353:2121–2134
  10. Scheen A, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660–1672
  11. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism. 2008;7:68–78
  12. Gromada J, Franklin I, Wollheim C. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocrine Reviews. 2007;28:84–116
  13. Göpel S, Kanno T, Barg S, et al. Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na+ channels. The Journal of Physiology. 2000;528:509–520
  14. Nadal A, Quesada I, Soria B. Homologous and heterologous asynchronicity between identified alpha-, beta- and delta-cells within intact islets of Langerhans in the mouse. The Journal of Physiology. 1999;517:85–93
  15. Zhang Q, Bengtsson M, Partridge C, et al. R-type Ca(2+)-channel-evoked CICR regulates glucose-induced somatostatin secretion. Nature Cell Biology. 2007;9:453–460
  16. Göpel S, Zhang Q, Eliasson L, et al. Capacitance measurements of exocytosis in mouse pancreatic alpha-, beta- and delta-cells within intact islets of Langerhans. The Journal of Physiology. 2004;556:711–726
  17. Dunning B, Foley J, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48:1700–1713
  18. Kurose T, Tsuda K, Ishida H, et al. Glucagon, insulin and somatostatin secretion in response to sympathetic neural activation in streptozotocin-induced diabetic rats. A study with the isolated perfused rat pancreas in vitro. Diabetologia. 1992;35:1035–1041
  19. Ashcroft F, Rorsman P. Electrophysiology of the pancreatic beta-cell. Progress in Biophysics and Molecular Biology. 1989;54:87–143
  20. Rorsman P, Eliasson L, Renström E, et al. The Cell Physiology of Biphasic Insulin Secretion. News in Physiological Sciences. 2000;15:72–77
  21. Fernandez J, Valdeolmillos M. Synchronous glucose-dependent [Ca(2+)](i) oscillations in mouse pancreatic islets of Langerhans recorded in vivo. FEBS Letters. 2000;477:33–36
  22. Santos R, Rosario L, Nadal A, et al. Widespread synchronous [Ca2+]i oscillations due to bursting electrical activity in single pancreatic islets. Pflügers Archiv: European Journal of Physiology. 1991;418:417–422
  23. Valdeolmillos M, Nadal A, Soria B, et al. Fluorescence digital image analysis of glucose-induced [Ca2+]i oscillations in mouse pancreatic islets of Langerhans. Diabetes. 1993;42:1210–1214
  24. Barbosa R, Silva A, Tomé A, et al. Real time electrochemical detection of 5-HT/insulin secretion from single pancreatic islets: effect of glucose and K+ depolarization. Biochemical and Biophysical Research Communications. 1996;228:100–104
  25. Gilon P, Shepherd R, Henquin J. Oscillations of secretion driven by oscillations of cytoplasmic Ca2+ as evidences in single pancreatic islets. The Journal of Biological Chemistry. 1993;268:22265–22268
  26. Ballian N, Brunicardi F. Islet vasculature as a regulator of endocrine pancreas function. World Journal of Surgery. 2007;31:705–714
  27. Cabrera O, Berman D, Kenyon N, et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:2334–2339
  28. Kiba T. Relationships between the autonomic nervous system and the pancreas including regulation of regeneration and apoptosis: recent developments. Pancreas. 2004;29:e51–e58
  29. Brunicardi F, Shavelle D, Andersen D. Neural regulation of the endocrine pancreas. International Journal of Pancreatology. 1995;18:177–195
  30. Love J, Szebeni K. Morphology and histochemistry of the rabbit pancreatic innervation. Pancreas. 1999;18:53–64
  31. Godfrey D, Matschinsky F. Enzymes of the cholinergic system in islets of Langerhans. The Journal of Histochemistry and Cytochemistry. 1975;23:645–651
  32. Furuzawa Y, Ohmori Y, Watanabe T. Anatomical localization of sympathetic postganglionic and sensory neurons innervating the pancreas of the cat. The Journal of Veterinary Medical Science / The Japanese Society of Veterinary Science. 1996;58:243–248
  33. Dunning B, Ahrén B, Veith R, et al. Nonadrenergic sympathetic neural influences on basal pancreatic hormone secretion. The American Journal of Physiology. 1988;255:E785–E792
  34. Ahrén B, Veith R, Paquette T, et al. Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 2. Effects on basal release of somatostatin and pancreatic polypeptide. Endocrinology. 1987;121:332–339
  35. Laychock S, Hoffman J, Meisel E, et al. Pancreatic islet arachidonic acid turnover and metabolism and insulin release in response to delta-9-tetrahydrocannabinol. Biochemical Pharmacology. 1986;35:2003–2008
  36. Juan-Picó P, Fuentes E, Bermúdez-Silva F, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 2006;39:155–162
  37. Matias I, Gonthier M, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3171–3180
  38. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regulatory Peptides. 2008;145:49–53
  39. Bermudez-Silva F, Sanchez-Vera I, Suárez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. European Journal of Pharmacology. 2007;565:207–211
  40. Starowicz K, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring, Md.). 2008;16:553–565
  41. Bermúdez-Silva F, Suárez J, Baixeras E, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 2008;51:476–487
  42. Tharp W, Lee Y, Maple R, et al. The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochemical and Biophysical Research Communications. 2008;372:595–600
  43. Grimsey N, Goodfellow C, Scotter E, et al. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!. Journal of Neuroscience Methods. 2008;171:78–86
  44. Jansson L, Carlsson P. Graft vascular function after transplantation of pancreatic islets. Diabetologia. 2002;45:749–763
  45. Henderson J, Daniel P, Fraser P. The pancreas as a single organ: the influence of the endocrine upon the exocrine part of the gland. Gut. 1981;22:158–167
  46. Maccarrone M, Fiori A, Bari M, et al. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thrombosis and Haemostasis. 2006;95:117–127
  47. Golech S, McCarron R, Chen Y, et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Research Molecular Brain Research. 2004;132:87–92
  48. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. The Journal of Neuroscience. 2002;22:9612–9617
  49. Hohmann A, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 1999;90:923–931
  50. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The Journal of Clinical Investigation. 2003;112:423–431
  51. Liu Y, Connoley I, Wilson C, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity (2005). 2005;29:183–187
  52. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation. 2005;115:1298–1305
  53. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843
  54. Rosenstock J, Hollander P, Chevalier S, et al. The SERENADE Trial: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naive type 2 diabetes. Diabetes Care. 2008;31:2169–2176
  55. Giuffrida A, Rodríguez de Fonseca F, Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Analytical Biochemistry. 2000;280:87–93
  56. Bermúdez-Silva F, Serrano A, Diaz-Molina F, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. European Journal of Pharmacology. 2006;531:282–284
  57. Leung D, Saghatelian A, Simon G &Cravatt B. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry. 2006;45:4720–4726
  58. Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414:209–212
  59. Cani P, Montoya M, Neyrinck A, et al. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. The British Journal of Nutrition. 2004;92:757–761
  60. González-Yanes C, Serrano A, Bermúdez-Silva F, et al. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. American Journal of Physiology. Endocrinology and Metabolism. 2005;289:E923–E929
  61. Guzmán M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). The Journal of Biological Chemistry. 2004;279:27849–27854
  62. Zhou Y, Shimabukuro M, Wang M, et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:8898–8903
  63. Gremlich S, Nolan C, Roduit R, et al. Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation. Endocrinology. 2005;146:375–382
  64. Overton H, Babbs A, Doel S, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metabolism. 2006;3:167–175
  65. Chu Z, Jones R, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology. 2007;148:2601–2609
  66. Akiba Y, Kato S, Katsube K, et al. Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochemical and Biophysical Research Communications. 2004;321:219–225
  67. Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochemical and Biophysical Research Communications. 2005;326:744–751
  68. Lauckner J, Jensen J, Chen H, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:2699–2704

PII: S1521-690X(08)00142-5

doi: 10.1016/j.beem.2008.10.012

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 87-102 , February 2009

Article Tools

* Image Usage & Resolution